文 | 医药研究社拿下一笔总额超12亿元的“license-out”后，荣昌生物及时交出了上半年的“成绩单”。财报显示，今年上半年，该公司实现营业收入10.98亿元，较去年同期增长48.02%；归母净利润-4.50亿元，上年同期为-7.81亿元，同比减亏42.40%；扣非净利润-4.46亿元，上年同期为-7.94亿元，同比减亏43.88%。绩后荣昌生物港股股价高开近4%。显而易见，荣昌生物冲刺速度...
Source Link文 | 医药研究社拿下一笔总额超12亿元的“license-out”后，荣昌生物及时交出了上半年的“成绩单”。财报显示，今年上半年，该公司实现营业收入10.98亿元，较去年同期增长48.02%；归母净利润-4.50亿元，上年同期为-7.81亿元，同比减亏42.40%；扣非净利润-4.46亿元，上年同期为-7.94亿元，同比减亏43.88%。绩后荣昌生物港股股价高开近4%。显而易见，荣昌生物冲刺速度...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.